top of page


Aro Biotherapeutics Names Seasoned Biopharma Industry Veteran Scott Greenberg as Vice President, Business Development and Alliance Management

Philadelphia, PA, December 10, 2019 – Aro Biotherapeutics Company announces that Scott Greenberg has joined the company as Vice President, Business Development and Alliance Management. He brings to the company a wealth of experience across a number of functional disciplines in both oncology and immunology garnered at Roivant Sciences and Celgene Corporation.


“Scott’s diverse experience at both large and small biopharmaceutical companies will be invaluable to Aro as we build our portfolio of proprietary and partnered Centyrin products,” stated Sue Dillon, PhD, co-founder and Chief Executive Officer of Aro Biotherapeutics. “We look forward to the impact he will make as we seek to establish strategic collaborations to leverage the power of our Centyrin technology.”


Mr. Greenberg most recently served as Vice President, Head of Operations at Roivant Sciences, where he was responsible for executive direction of newly established clinical-stage companies. Prior to Roivant, he spent more than a decade at Celgene Corporation (now BMS/Celgene) in multiple roles spanning business development, alliance management, operations, R&D project leadership, sales and marketing. He began his career in investment banking at Goldman Sachs & Co. Mr. Greenberg has a dual degree, with a BS in Economics and a BA in Biological Basis of Behavior with a minor in Mathematics, from the University of Pennsylvania as well as an MBA from Harvard Business School. 


Building a Pipeline of Life Changing Therapies

Centyrins are small, structurally simple, ultra-stable, highly soluble proteins. These characteristics enable the discovery of medicines with new mechanisms of action for cancer and other devastating diseases. This first-of-its-kind combination of properties is designed to address unmet medical needs by targeting drug payloads in high concentration to the site of disease, while lowering the toxicity to non-target organs. The company holds an exclusive worldwide license for research, development, manufacturing and commercialization of Centyrin protein therapeutics.


About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for tissue specific targeting of therapeutics, including nucleic acid drugs for a diverse set of diseases. For more information, visit


CENTYRIN™ is a trademark of Johnson & Johnson.


Media Contact

Mike Beyer

Sam Brown Inc.


bottom of page